Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Poland Sp. z o.o.
Ul. Poleczki 35
Budynek A1
02-822 Warsaw
Poland
Phone: +48 22 351 51 00
Fax: +48 22 351 51 01
www.biogenidec.pl
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market,…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here